Clinical trial
Radiation Therapy With or Without RSR13 in Treating Patients With Brain…
NCT00005887 · Spectrum Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00005887 |
|---|---|
| Title | Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases |
| Official title | A Phase III, Randomized, Open-Label, Comparative Study of Standard Whole Brain Radiation Therapy With or Without RSR13 in Patients With Brain Metastases |
| Lead sponsor | Spectrum Pharmaceuticals, Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Cancer |
| Intervention type | Drug, Radiation |
| Interventions | efaproxiral, radiation therapy |
| Start date | Feb 1, 2000 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Aug 29, 2003 |
| Last update posted | Aug 23, 2021 |
| Countries | Australia, Belgium, Canada, France, Germany, Hungary, Italy, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: